Skip to main content

Ariadna Laguna Tuset

I am a neuroscientist with extensive experience in the molecular mechanisms underlying both neurodevelopmental and neurodegenerative diseases of the nervous system. My current research is aimed at identifying new therapeutic targets and biomarkers to improve the diagnosis and treatment of Parkinson's disease.

Institutions of which they are part

Main researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Ariadna Laguna Tuset

Institutions of which they are part

Main researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

I am a neuroscientist with extensive experience in the molecular mechanisms underlying both neurodevelopmental and neurodegenerative diseases of the nervous system. My current research is aimed at identifying new therapeutic targets and biomarkers to improve the diagnosis and treatment of Parkinson's disease.

I received my Biology degree, Health and Life Sciences specialization, in 2003 at the Universitat Pompeu Fabra (Barcelona, Spain). I got my Ph.D. in 2008 in the laboratory of Dr. Mariona Arbonés at the Center for Genomic Regulation (CRG, Barcelona, Spain). My Ph.D. was devoted to study the molecular basis of Down Syndrome neurological alterations. In 2009, I joined the group of Professor Thomas Perlmann at the Ludwig Institute for Cancer Research – Karolinska Institutet (Stockholm, Sweden) as a post-doctoral Marie Curie researcher to work on the transcriptional regulation of dopamine neurons during development and in pathological conditions such as Parkinson’s disease.

In 2014, I moved back to Barcelona and joined the Neurodegenerative Diseases Research Group at the Vall d’Hebron Research Institute (VHIR) as a Beatriu de Pinós post-doctoral researcher funded by AGAUR-FP7 Marie Curie Actions. Afterwards, I received a Young Investigator contract from the Spanish government (Ministry of Economy and Competitiveness (MINECO)) and a Junior Leader fellowship from the La Caixa Foundation to establish my own research lines within the group. In addition, I am an associate researcher at the Neuroscience Institute of the Autonomous University of Barcelona (UAB) and Scientific Ambassador of the World Parkinson Coalition.

The research from my team is devoted to elucidate the molecular mechanisms of inter-organ communication in Parkinson’s disease and how this contributes to the pathophysiology and symptoms of this neurodegenerative disorder. Our research contributes to: (i) identify biomarkers for early detection, disease progression or response to treatment, (ii) identify new molecular targets and develop novel therapeutic strategies with disease-modifying potential, (iii) unravel molecular pathways common to other neurodegenerative or metabolic diseases. Researcher ID: F-9561-2016; Orcid: 0000-0002-9732-6677.

Projects

Activity and connectivity drive neuronal vulnerability and disease progression in Parkinson's disease

IP: Miquel Vila Bover
Collaborators: Joan Compte Barrón, Javier Hoyo Pérez, Gerard Roch Alba, Marta González Sepúlveda, Ariadna Laguna Tuset, Joana Margalida Cladera Sastre
Funding agency: Michael J. Fox Foundation
Funding: 1269495.05
Reference: ASAP_MJFF2021
Duration: 01/11/2021 - 31/10/2024

The brain-body axis in Parkinson’s disease patients: from pathophysiology to biomarkers and therapeutic approaches

IP: Ariadna Laguna Tuset
Collaborators: Maria Victoria Gonzalez Martinez, Miquel Vila Bover, Marina Lorente Picón, Helena Xicoy Cortada, Daniela Samaniego Toro, Sara Belmonte Calderon
Funding agency: Instituto de Salud Carlos III
Funding: 171820
Reference: PI21/01603
Duration: 01/01/2022 - 31/12/2024

The Gut-Brain axis in Parkinson's disease: novel pathogenic mechanisms and new possibilities for biomarkers and therapeutic approaches

IP: Ariadna Laguna Tuset
Collaborators: Marina Lorente Picón, Helena Xicoy Cortada
Funding agency: Fundació "La Caixa"
Funding: 303300
Reference: 2018_INCOMING_CAIXA/LAGUNA
Duration: 02/10/2019 - 30/04/2023

Modulation of age-dependent neuromelanin accumulation as a novel therapeutic strategy for Parkinson’s disease and brain aging

IP: Miquel Vila Bover
Collaborators: Ariadna Laguna Tuset, Thais Cuadros Arasa, Marta González Sepúlveda, Annabelle Parent
Funding agency: Fundació "La Caixa"
Funding: 466004
Reference: FBLC/HR17-00513/VILA
Duration: 01/09/2018 - 05/01/2022

Related news

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Dr. Miquel Vila, head of the Neurodegenerative Diseases research group at VHIR, is the co-chair of the local organising committee. And Dr. Ariadna Laguna, principal investigator of the same group, is a scientific ambassador.

Related professionals

Franco Marinello

Franco Marinello

Senior researcher
General Surgery
Read more
Lorena Villa García

Lorena Villa García

Predoctoral researcher
Research on Aging, Frailty and Transitions in Barcelona
Read more
Ana Gallego Cortes

Ana Gallego Cortes

Predoctoral researcher
Infectious Diseases
Read more
Maider Arando Lasagabaster

Maider Arando Lasagabaster

Infectious Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.